Table 4.

Summary of risankizumab trough plasma concentrations (µg/mL) in patients with moderate-to-severe plaque psoriasis across all phase III studies

Risankizumab 150 mg SC groupa	Geometric mean (arithmetic mean, %CV)
	Week 4	Week 16	Week 28	Week 40	Week 52
	[n = 1065]	[n = 1057]	[n = 1038]	[n = 750]	[n = 721]
Total across phase III studies	5.47 (5.89, 38)	1.84 (2.27, 60)	1.60 (1.98, 60)	1.57 (2.00, 75)	1.52 (1.94, 65)
	[n = 177]	[n = 175]	[n = 173]	[n = 166]	[n = 156]
Japanese patients only across phase III studies	5.23 (5.65, 38)	1.70 (2.16, 71)	1.39 (1.78, 65)	1.46 (1.94, 89)	1.42 (1.85, 66)

SC subcutaneous, %CV percentage coefficient of variation

^aSubjects received a risankizumab dose at weeks 0 and 4, and every 12 weeks thereafter